O cerco do FDA ao que consideram prática abusiva de marketing leva outra empresa farmacêutica ao banco dos réus no mercado Americano. O Johnson&Johnson é acusada de prática abusiva, em conjunto com a Ominicare, empresa de prestação de serviços de saúde. Leia a íntegra abaixo, publicada no dia 16 de Janeiro último no The Wall Street Journal.
BY JONATHAN D. ROCKOFF
In the latest case in the government's campaign against abusive drug-marketing practices, the Justice Department charged Johnson & Johnson with paying "tens of millions of dollars in kickbacks" to a nursing-home pharmacy company to boost sales of J&J drugs to nursing-home patients.
Prosecutors, in a complaint filed in federal court in Boston Friday, accused J&J of illegally paying Omnicare Inc. to buy J&J medicines and recommend their use to nursing homes. Under the arrangements, prosecutors alleged, Omnicare's annual purchases of J&J medicines nearly tripled to more than $280 million.
The drugs included the blockbuster antipsychotic Risperdal, which was prescribed to
In the latest case in the government's campaign against abusive drug-marketing practices, the Justice Department charged Johnson & Johnson with paying "tens of millions of dollars in kickbacks" to a nursing-home pharmacy company to boost sales of J&J drugs to nursing-home patients.
Prosecutors, in a complaint filed in federal court in Boston Friday, accused J&J of illegally paying Omnicare Inc. to buy J&J medicines and recommend their use to nursing homes. Under the arrangements, prosecutors alleged, Omnicare's annual purchases of J&J medicines nearly tripled to more than $280 million.
The drugs included the blockbuster antipsychotic Risperdal, which was prescribed to
Nenhum comentário:
Postar um comentário
Seus comentários são bem-vindos, agradeço por ler meu blog e comentá-lo. Responderei ao seu comentário se assim o indicar.